Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

European shares edge down, Melrose and Subsea impress

Published 02/03/2017, 10:48
© Reuters. Traders work at their desks in front of the German share price index DAX board in Frankfurt

By Helen Reid

LONDON (Reuters) - European shares edged back on Thursday after a strong rally in the previous session, though there were strong gains from Britain's Melrose and Norway's Subsea after well-received results.

The pan-European STOXX 600 (STOXX) index was down 0.1 percent. Utilities stocks (SX6P) were the top gainers while real estate stocks (SX86P) were the biggest losers.

The European earnings season was moving into its latter stages with figures having impressed so far.

"With 75 percent of companies having reported, STOXX 600 Q4 earnings per share are up 12.1 percent year on year, the strongest number since Q4 2013," Deutsche Bank (DE:DBKGn) analysts said.

British mid-cap engineering turnaround specialist Melrose Industries (L:MRON) was the top gainer and hit a record high, last up 13.5 percent, after its full-year revenue more than tripled, helped by its acquisition of U.S. ventilation maker Nortek Industries.

Subsea 7 (OL:SUBC), the Norwegian oil services company, was up 11.5 percent after it posted a fourth-quarter earnings beat and said it would pay a special dividend.

The firm had been a short selling target, with 8.8 percent of it shares outstanding on loan according to IHS Markit, though this number diminished 10 percent in the past month.

Engie, the French gas and power company, was the top CAC 40 (FCHI) gainer, up 6.2 percent and headed for its best day in nearly 5 1/2 years after it posted 2016 earnings in line with analysts' expectations.

Engie, which is 28.7 percent government-owned, said it could achieve 85 percent of its planned asset sales by the end of 2017, and announced the acquisition of British company Keepmoat Regeneration.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Successful drug trials helped shares of Swiss pharmaceuticals company Roche (S:ROG) to gain 5.2 percent, on track for its best daily gains in eight years. Its Perjeta and Herceptin drugs reduced the recurrence of aggressive breast cancer, its key Aphinity study found.

French advertiser JC Decaux (PA:JCDX) was a top gainer, up 4.2 percent after its results came in ahead of analysts' consensus. Its shares hit their highest level since early June 2016.

British outsourcing firm Capita (L:CPI) sank to the bottom of the STOXX, down 7.3 percent after posting disappointing results and announcing its CEO's departure.

British housebuilder Travis Perkins (L:TPK) was a top European faller after it posted a decline in profit due to weak performance in its plumbing and heating business.

Italian eyewear maker Luxottica, in focus due to its mega-merger with French lens maker Essilor, was down 3.2 percent, the FTSE MIB top faller after it posted a slight drop in profit for 2016 after market close on Wednesday.

"We think this is good enough in this phase, as focus is on the planned merger with Essilor," Deutsche Bank analysts said, adding retail profit evolution and Ray-Ban overall performance would be their areas of focus in the call with investors.

The world's largest provider of temporary staff Adecco (S:ADEN) was among top fallers, down 3.9 percent despite reporting better-than-expected fourth-quarter earnings.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.